BRAWM Trial Update from Dr. Neil Berinstein

On Feb. 9th 2022, Dr. Neil Berinstein of the Sunnybrook Cancer Research Institute provided us with an update on the BRAWM trial.  That trial combines the standard-of-care Bendamustine + Rituximab, but adds in a BTK inhibitor, Acalabrutinib.

He also gave us an view of how Covid impacts WM patients.

And there was time for Q&A on both topics.

View the video here, on the WMFC YouTube channel.